MIAMI, Florida — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (“UAB”) for its ongoing Phase 1/1b open-label study evaluating PAS-004...
Latest News
MIAMI, FL — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the ALS Association has awarded a Hoffman ALS Clinical Trial Award grant worth ~$1 million to study PAS-004 in ALS patients. The award was given...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Florida — Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the activation of four clinical trial sites in the United States. These...
MIAMI, Florida — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the Company has completed enrollment and initial dosing of three subjects in...
MIAMI, FL — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced positive tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients...
BUFFALO, NY – A new research paper was published in Volume 16 of Genes & Cancer on January 20, 2025, entitled, “Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.” Researchers from Instituto de Física Universidad Autónoma de San Luis Potosí and Hospital Central “Ignacio Morones...
Hong Kong – Amyotrophic Lateral Sclerosis (ALS) is a fatal type of motor neuron disease characterized by progressive degeneration of nerve cells in the spinal cord and brain, resulting in muscle weakness and paralysis that can include the inability to walk and speak, or even swallow and breathe. The average...
MIAMI, FLORIDA – In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of...
Barcelona, Spain – Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug targets changes in the FGFR3 gene that drive tumour growth in about 10%-20% of these patients....
Alexandria, VA. Patients in the phase 3 CheckMate-649 trial (NCT02872116) who received nivolumab (Opdivo) plus chemotherapy reported stable or better on-treatment health-related quality of life (HRQOL) compared with chemotherapy alone. CheckMate-649 included patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, and findings were published in...